Research advances in obeticholic acid and fibrates in treatment of primary biliary cholangitis with poor response or intolerance to ursodeoxycholic acid
10.3969/j.issn.1001-5256.2022.04.035
- VernacularTitle:对熊去氧胆酸应答不佳或不耐受的原发性胆汁性胆管炎患者应用奥贝胆酸和贝特类药物治疗的研究进展
- Author:
Junfang SHUAI
1
;
Ziyan HAN
1
Author Information
1. Department of Gastroenterology, The Second Hospital of Shanxi Medical University, Taiyuan 030001, China
- Publication Type:Reviews
- Keywords:
Primary Biliary Cholangitis;
Ursodeoxycholic Acid;
Obeticholic Acid;
Fenofibrate;
Bezafibrate
- From:
Journal of Clinical Hepatology
2022;38(4):913-917
- CountryChina
- Language:Chinese
-
Abstract:
Poor response or intolerance to ursodeoxycholic acid may occur in the treatment of primary biliary cholangitis (PBC), and after switch to obeticholic acid or fibrates alone or in combination, poor response or intolerance is also observed in some treatment regimens. Clinical studies on obeticholic acid and fibrates will gradually solve these issues, and obeticholic acid/fibrates combined with ursodeoxycholic acid is safe and effective in PBC patients without advanced liver cirrhosis.
